Efficacy of Euminz® for Tension-Type Headache (CAS/B/016611)

Charité University Medicine Berlin

Status and phase: Completed; Phase 4

Conditions: Episodic Tension-Type Headache

Treatments: Drug: Placebo; Drug: Euminz®

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01770080

2011-004777-89

Details and patient eligibility

About

Efficacy and safety of Euminz® (10% ethanolic solution of peppermint oil for topical use) compared to placebo in patients with episodic tension-type headache (ETTH).

Prospective, double-blind, placebo-controlled, phase IV clinical trial; Parallel-groups design; Randomisation 1:1; First attack per patient will be evaluated for primary objectives, following attacks during study duration will be observed and documented.

Study duration per patient: 10 weeks

Full description

To demonstrate the efficacy of Euminz® to reduce the intensity of headache symptoms experienced by patients with episodic tension-type headache. The two primary objectives will be tested hierarchically (a-priory ordered) to avoid alpha-adjustment:

First primary objective of the first headache episode is "pain-free" (0 or 1) after 2 hours measured on a six-step verbal pain rating scale (VPRS). Acute treatment (3 to 5 time topical use of Euminz®) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).

Second primary objective of the first headache episode will be the decrease of intensity of pain measured by a visual analogue scale (VAS). The difference from measure point 0 (before first application of Euminz®) on the VAS in comparison to 15, 30, 45, 60, 90 and 120 minutes after start of treatment will be shown as area under the curve representing the pain intensity difference (PID).

Enrollment: 211 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients from 18 years onwards
• History of ETTH for at least one year. The number of days with such a headache is ≥2 per month
• Onset of TTH below 65 years of age
• At least 10 previous headache attacks fulfilling the following four inclusion criteria:
• Patients with headache attacks lasting from 30 minutes to 7 days
• At least two of the following pain characteristics are present:
• • Pressing or tightening (non-pulsating) quality
• • Intensity of pain: moderate = unable to ignore (pain may inhibit, but does not prohibit activities)
• • Bilateral location
• • No aggravation by walking stairs or similar routine physical activity
• Headache is not accompanied by nausea or vomiting (anorexia may occur)
• Headache is not accompanied by a combination of the following symptoms: photophobia and phonophobia (only one may be present)
• 3 months retrospective history
• Willingness and ability to keep the patient's diary and to comply with the procedures of the study
• Written informed consent

Exclusion criteria

• Headaches other than TTH: (e.g. migraine, cluster headache, hypertension headache, drug-related headache,analgesic-induced headache,post-traumatic headache; associated migraine attacks are permitted if they are well recognized by the patient and if their frequency during the preceding year has not exceeded one per month)
• Presence of oromandibular dysfunction
• History of facial or cranial surgery
• Use of prophylactic drugs for headache within one month prior to enrolment
• Use of drugs for acute TTH treatment for ≥ 10 days of headache per month
• Anticipated problems in adhering to the self-observation procedure (e.g. because of work)
• Abuse of alcohol, narcotics or other drugs
• Serious illnesses within the last 3 months (e.g. myocardial infarction, cardiac insufficiency NYHA III and IV, low blood pressure, cerebral insult, diabetes mellitus, neuropathy, changes in the skin or neoplasms in the head)
• Epilepsy
• Intake of anti-psychotic, anti-depressant or anti-epileptic medication during the previous month
• Intake of long-acting non-steroidal anti-inflammatory drugs within the last month
• Planned start of new pharmacological or non-pharmacological therapies
• Any significant skin condition affecting face or neck
• Known hypersensitivity towards peppermint oil
• Previous use of Euminz® or any other essential oil solutions for headache in the last three months
• Participation in another clinical trial within the last month
• Accommodation in an institution at judicial or official request

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

211 participants in 2 patient groups, including a placebo group

Euminz®

Active Comparator group

Description:

Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).

Treatment:

Drug: Euminz®

Placebo

Placebo Comparator group

Description:

Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).

Treatment:

Drug: Placebo